| Product Unit Size | Cost | Quantity | Stock |
|---|
CFI-400945 is an inhibitor of polo-like kinase 4 (PLK4). PLK4 plays an important role in centriole replication, and inhibition of PLK4 disrupts mitosis. CFI-400945 inhibits tumor growth in models of pancreatic cancer. PLK4 inhibition may be effective against osteosarcoma, where it is theorized that overexpression of PLK4 may be a driving forc ein osteosarcoma development and preservation. TEST!!!!!!
| Cas No. | 1338806-73-7 |
|---|---|
| Purity | ≥98% |
| Formula | C33H34N4O3 |
| Formula Wt. | 534.66 |
| IUPAC Name | (1R,2S)-2-{3-[(E)-2-(4-{[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl}phenyl)vinyl]-1H-indazol-6-yl}-5'-methoxyspiro[cyclopropane-1,3'-indol]-2'(1'H)-one |
| Synonym | CFI 400945, CFI400945 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Lohse I., Mason J., et al. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. Oncotarget. 8(2):3064-71 (2017). PMID: 27902970.
Kelleher F., Kores J., et al. Targeting the centrosome and polo-like kinase 4 in osteosarcoma. Carcinogenesis. 40(4):493-99 (2019). PMID: 30508038.